CSPC Pharmaceutical Group Limited (1093.HK)

6,880 +0,020 (+0,29 %) À partir de 01:55PM HKT. Marché ouvert.

CSPC Pharmaceutical Group Limited

No. 226 Huanghe Street
Shijiazhuang 050035
China
86 31 1870 37015
https://www.cspc.com.hk

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 23 500

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Dongchen Cai	Executive Chairman	20,02M	S.O.	1954
Mr. Cuilong Zhang	Vice-Chairman & CEO	10,64M	S.O.	1969
Mr. Chunlei Li	Executive Director & Chief Scientist	7,24M	S.O.	1976
Mr. Kin Man Chak	Executive Director	5,3M	S.O.	1966
Mr. Weidong Pan	Executive Director	3,85M	S.O.	1969
Mr. Huaiyu Wang	Executive Director	4,73M	S.O.	1963
Mr. Zhenguo Wang	Executive Director	3,83M	S.O.	1970
Dr. Qingxi Wang Ph.D.	Executive Director	3,34M	S.O.	1966
Dr. Hao Jiang	Executive Director	2,88M	S.O.	1984

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en HKD.

Description

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Gouvernance d’entreprise

L’ISS Governance QualityScore de CSPC Pharmaceutical Group Limited en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 9; Société : 6; Droits des actionnaires : 4; Compensation : 9.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.